Latest News
Conference Coverage
Edoxaban noninferior to dalteparin for cancer-associated VTE
ATLANTA – Twelve months of daily edoxaban was noninferior to subcutaneous therapy with dalteparin for VTE in patients with cancer.
Conference Coverage
VIDEO: Venetoclax/rituximab prolongs PFS in relapsed/refractory CLL
ATLANTA – Dr. John Seymour discussed results from a study comparing bendamustine/rituximab with venetoclax/rituximab in relapsed/refractory CLL...
Conference Coverage
Daratumumab plus VMP boosts PFS, MRD-negativity in de novo myeloma
ATLANTA – The study included patients with new onset multiple myeloma who were not eligible for transplant.
Conference Coverage
VIDEO: Daratumumab gives kick to standard first-line myeloma therapy
Dr. Jesus San-Miguel discusses results of the ALCYONE study and recent advances in the treatment of multiple myeloma.
Conference Coverage
Azacitidine maintenance improves PFS in older AML patients
ATLANTA – A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy.
Conference Coverage
PANACEA: pembrolizumab overcomes trastuzumab resistance for some
SAN ANTONIO – Pembrolizumab overcomes trastuzumab resistance in some HER2-positive advanced breast cancer if the tumor expresses PD-L1.
From the Journals
Flu vaccine did not protect children with acute leukemia
Receiving a trivalent inactivated influenza vaccine (TIV) did not protect children and adolescents with acute leukemia from developing the flu,...
Conference Coverage
Novel PARP inhibitor boosts PFS in HER2- breast cancer with BRCA mutations
SAN ANTONIO – PARP inhibitor talazoparib was associated with a near doubling in progression-free survival when compared with single-agent...
Conference Coverage
Extra years of adjuvant bisphosphonate not needed in early breast cancer
SAN ANTONIO - Neither adapted disease-free survival nor overall survival were significantly better with 3 extra years of zoledronate therapy.
Conference Coverage
VIDEO: CAR T cell axi-cel drives B-cell lymphomas into remission
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Conference Coverage
Three-month response to CAR T-cells looks durable in DLBCL
ATLANTA – A quarter of the patients in the study were infused as outpatients.